Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

0.4750
+0.03507.95%
Volume:8.02M
Turnover:3.95M
Market Cap:37.63M
PE:-0.33
High:0.5199
Open:0.5155
Low:0.4700
Close:0.4400
Loading ...

Piper bullish on Tenaya, says initial MyPEAK-1 data de-risks higher dosing

TIPRANKS
·
17 Dec 2024

Positive Buy Recommendation for Tenaya Therapeutics Based on Promising TN-201 Gene Therapy Results

TIPRANKS
·
17 Dec 2024

Promising Early Data from Tenaya Therapeutics’ TN-201 Program Justifies Buy Rating

TIPRANKS
·
17 Dec 2024

Tenaya Says TN-201 Gene Therapy Well Tolerated in Initial Hypertrophic Cardiomyopathy Trial Patients

MT Newswires Live
·
17 Dec 2024

Tenaya Therapeutics’ Senior VP Resigns for New Opportunity

TIPRANKS
·
17 Dec 2024

Tenaya Therapeutics Inc - Chihro Saito Resigns as Svp, Afo and Interim Pao of Tenaya

THOMSON REUTERS
·
17 Dec 2024

Tenaya reported early data from first cohort of patients in MyPEAK-1 trial

TIPRANKS
·
17 Dec 2024

Tenaya Therapeutics Reports Promising Early Data From Mypeak™-1 Phase 1B/2 Clinical Trial of Tn-201 for Treatment of Mybpc3-Associated Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
17 Dec 2024

Tenaya Therapeutics Inc - Tn-201 Well Tolerated With Increasing Rna and Protein Levels

THOMSON REUTERS
·
17 Dec 2024

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire
·
17 Dec 2024

Tenaya Therapeutics to announce initial data from Phase 1b/2 trial of TN-201

TIPRANKS
·
17 Dec 2024

BRIEF-Tenaya Therapeutics To Announce Initial Data From Mypeak-1 Phase 1B/2 Clinical Trial Of TN-201 Gene Therapy For Mybpc3-Associated Hypertrophic Cardiomyopathy On Tuesday, December 17, 2024

Reuters
·
17 Dec 2024

Tenaya Therapeutics to Announce Initial Data From Mypeak-1 Phase 1B/2 Clinical Trial of Tn-201 Gene Therapy for Mybpc3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

THOMSON REUTERS
·
17 Dec 2024

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

GlobeNewswire
·
17 Dec 2024

Tenaya Therapeutics Price Target Announced at $18.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Nov 2024

Positive Outlook for Tenaya Therapeutics Amidst Strategic Advancements in PKP2-ARVC Gene Therapy

TIPRANKS
·
26 Nov 2024